Michael E Abram
Overview
Explore the profile of Michael E Abram including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
1164
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wilkins D, Yuan Y, Chang Y, Aksyuk A, Nunez B, Wahlby-Hamren U, et al.
Nat Med
. 2024 Apr;
30(6):1785.
PMID: 38649782
No abstract available.
2.
Ahani B, Tuffy K, Aksyuk A, Wilkins D, Abram M, Dagan R, et al.
Nat Commun
. 2024 Apr;
15(1):3026.
PMID: 38589384
No abstract available.
3.
Ahani B, Tuffy K, Aksyuk A, Wilkins D, Abram M, Dagan R, et al.
Nat Commun
. 2023 Jul;
14(1):4347.
PMID: 37468530
Nirsevimab is a monoclonal antibody that binds to the respiratory syncytial virus (RSV) fusion protein. During the Phase 2b (NCT02878330) and MELODY (NCT03979313) clinical trials, infants received one dose of...
4.
Wilkins D, Yuan Y, Chang Y, Aksyuk A, Nunez B, Wahlby-Hamren U, et al.
Nat Med
. 2023 Apr;
29(5):1172-1179.
PMID: 37095249
Nirsevimab is an extended half-life monoclonal antibody specific for the prefusion conformation of the respiratory syncytial virus (RSV) F protein, which has been studied in preterm and full-term infants in...
5.
Wilkins D, Langedijk A, Lebbink R, Morehouse C, Abram M, Ahani B, et al.
Lancet Infect Dis
. 2023 Mar;
23(7):856-866.
PMID: 36940703
Background: Nirsevimab is an extended half-life monoclonal antibody to the respiratory syncytial virus (RSV) fusion protein that has been developed to protect infants for an entire RSV season. Previous studies...
6.
Brady T, Zhang T, Tuffy K, Haskins N, Du Q, Lin J, et al.
Microbiol Spectr
. 2022 Aug;
10(5):e0103422.
PMID: 35993765
AZD7442, a combination of two long-acting monoclonal antibodies (tixagevimab [AZD8895] and cilgavimab [AZD1061]), has been authorized for the prevention and treatment of coronavirus disease 2019 (COVID-19). The rapid emergence of...
7.
Hammitt L, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Madhi S, et al.
N Engl J Med
. 2022 Mar;
386(9):837-846.
PMID: 35235726
Background: Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infection and hospitalization in infants. Nirsevimab is a monoclonal antibody to the RSV fusion protein that has...
8.
OToole A, Pybus O, Abram M, Kelly E, Rambaut A
BMC Genomics
. 2022 Feb;
23(1):121.
PMID: 35148677
Background: More than 2 million SARS-CoV-2 genome sequences have been generated and shared since the start of the COVID-19 pandemic and constitute a vital information source that informs outbreak control,...
9.
Loo Y, McTamney P, Arends R, Abram M, Aksyuk A, Diallo S, et al.
Sci Transl Med
. 2022 Jan;
14(635):eabl8124.
PMID: 35076282
Despite the success of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines, there remains a need for more prevention and treatment options for individuals remaining at risk of coronavirus disease...
10.
Tabor D, Fernandes F, Langedijk A, Wilkins D, Lebbink R, Tovchigrechko A, et al.
J Clin Microbiol
. 2020 Oct;
59(1).
PMID: 33087438
Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infection among infants and young children, resulting in annual epidemics worldwide. INFORM-RSV is a multiyear clinical study designed...